Vaccination strategies in lymphoproliferative disorders: Failures and successes
作者： A. Allegra , S. Russo , D. Gerace , L. Calabrò , V. Maisano
DOI: 10.1016/J.LEUKRES.2015.08.001
关键词: Tumor Escape 、 Antigen 、 Immunology 、 Cancer 、 Immunotherapy 、 Lymphoproliferative disorders 、 Tumor microenvironment 、 Medicine 、 Vaccination 、 Immune system
摘要: Anti-tumor vaccines in lymphoproliferative disorders hold out the prospect of effective tumor therapies with minimal side effects. The addition immunotherapy to old and new chemotherapy regimens has improved both response rates disease-free survival, leading many cases an extended overall survival. Ideally, antigen that is used for vaccination would be specifically expressed tumor; it must have important, causal part multifactorial process leads cancer, stably even after attacked by immune system. Immunotherapies, which aim activate system kill cancer cells, include strategies increase frequency or potency antitumor T overcome suppressive factors microenvironment, reduce T-cell suppression systemically. In this review, we focus on results clinical trials lymphoma, discuss potential enhance efficacy future.
elsevier.com
sci-hub.se 参考文章(149)
Jianli Wang, John Krauss, Xuetao Cao, Scott Saffold, Wei Chen, Eliciting T Cell Immunity Against Poorly Immunogenic Tumors by Immunization with Dendritic Cell-Tumor Fusion Vaccines Journal of Immunology. ,vol. 161, pp. 5516- 5524 ,(1998)
Sally R. M. Bennett, Francis R. Carbone, Freda Karamalis, Richard A. Flavell, Jacques F. A. P. Miller, William R. Heath, Help for cytotoxic-T-cell responses is mediated by CD40 signalling Nature. ,vol. 393, pp. 478- 480 ,(1998) , 10.1038/30996
Maurizio Bendandi, Christopher D. Gocke, Carol B. Kobrin, Floyd A. Benko, Lars A. Sternas, Robin Pennington, Thelma M. Watson, Craig W. Reynolds, Barry L. Gause, Patricia L. Duffey, Elaine S. Jaffe, Stephen P. Creekmore, Dan L. Longo, Larry W. Kwak, Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine. ,vol. 5, pp. 1171- 1177 ,(1999) , 10.1038/13928
S. Manzur, S. Cohen, J. Haimovich, N. Hollander, Enhanced therapeutic effect of B cell‐depleting anti‐CD20 antibodies upon combination with in‐situ dendritic cell vaccination in advanced lymphoma Clinical and Experimental Immunology. ,vol. 170, pp. 291- 299 ,(2012) , 10.1111/J.1365-2249.2012.04658.X
Tracy Beil, Roger Chou, Craig Fleming, Christina Bougatsos, Tracy Dana, Inclusion and Exclusion Criteria Agency for Healthcare Research and Quality (US). ,(2011)
Ivan Borrello, Eduardo M. Sotomayor, Frédérique-Marie Rattis, Sara K. Cooke, Lingping Gu, Hyam I. Levitsky, Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood. ,vol. 95, pp. 3011- 3019 ,(2000) , 10.1182/BLOOD.V95.10.3011
John Paul Ridge, Francesca Di Rosa, Polly Matzinger, A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell Nature. ,vol. 393, pp. 474- 478 ,(1998) , 10.1038/30989
Stephen P. Schoenberger, Rene E. M. Toes, Ellen I. H. van der Voort, Rienk Offringa, Cornelis J. M. Melief, T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions Nature. ,vol. 393, pp. 480- 483 ,(1998) , 10.1038/31002
Sonja Schafnitzel, Gert Riethmüller, Helmut E. Feucht, Brigitte Kluth, Sigrun Hess, Hartmut Engelmann, Endothelial Expression of CD40 in Renal Cell Carcinoma Cancer Research. ,vol. 57, pp. 891- 899 ,(1997)
James L. M. Ferrara, Silke Gillessen, Takanori Teshima, Nicolas Mach, Luying Pan, Geoffrey R. Hill, Glenn Dranoff, Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation Cancer Research. ,vol. 61, pp. 162- 171 ,(2001)